News Results for GlaxoSmithKline (GSK)

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1550p (from 1520p). Story provided by StockMarketWire.com Broker Forecasts...

Bryan Garnier today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1660p (from 1710p). Story provided by StockMarketWire.com Broker Forecasts...

Sir Philip Hampton, Chairman, bought 2,790 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 54,241 shares representing 0.00% of the shares in issue. Story...

Manvinder Banga, Non Executive Director, bought 458 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 3,861 shares representing 0.00% of the shares in issue....

Dr Vivienne Cox, Non Executive Director, bought 339 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 3,971 shares representing 0.00% of the shares in issue....

Urs Rohner, Non Executive Director, bought 458 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 8,522 shares representing 0.00% of the shares in issue....

Pharmaceuticals giant GlaxoSmithKline posted a rise in first-quarter earnings and reaffirmed its annual guidance following strong sales of its shingles vaccine and HIV treatments. Earnings per...

GlaxoSmithKline said its ViiV Healthcare joint venture had submitted a new drug application to the FDA seeking approval for two-drug HIV treatment regime. The monthly and injectable regimen...

Simon Dingemans, Financial Director, has re-invested 4,619 shares in the company on the 12th April 2019 at a price of 1565.60p. The Director now holds 99,648 shares representing 0.00% of the shares...

Emma Walmsley, Chief Executive Officer, has re-invested 1,856 shares in the company on the 15th April 2019 at a price of 1550.09p. The Director now holds 682,108 shares. Story provided by...

Global equities fell into the red after US President Donald Trump threatened tariffs on $11bn of European goods. At close, the FTSE 100 was 0.3% lower at 7,425. Elsewhere, European equities also...

The FTSE 100 was up a handful of points by midday at 7,455.71 with investors weighing the latest Brexit developments, as Theresa May headed to Berlin, as well as rising tensions between the EU and...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer received regulatory approval for its two-drug treatment for HIV from the US Food and Drug Administration. Dovato, a two-drug...

Weak economic data from the US and China weighed on global equities, as they added to concerns over global growth. The FTSE 100 fell 0.7% to 7,104. US jobs data was weaker than expected after...

Weak Chinese export data dialed up fears on global growth and sent the FTSE 100 sharply into reverse with US jobs numbers to come this afternoon. By midday the index of leading UK shares was down...

Shore Capital today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to hold (from buy). Story provided by StockMarketWire.com Broker Forecasts data provided by...

GlaxoSmithKline said Friday its ViiV Healthcare joint venture with Pfizer had recorded positive results from two clinical trials of an injectable two-drug regime for the treatment of HIV. The...

Britain's Serious Fraud Office said it had dropped investigations into individuals at GlaxoSmithKline and Rolls-Royce. 'After an extensive and careful examination I have concluded that there is...

UBS today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to neutral (from buy) and cut its price target to 1650p (from 1700p). Story provided by StockMarketWire.com Broker...

Simon Dingemans, Financial Director, exercised 68,442 shares in the company on the 18th February 2019 at a price of 0.00p. The Director now holds 982,153 shares. Story provided by...

Simon Dingemans, Financial Director, sold post-exercise 32,218 shares in the company on the 18th February 2019 at a price of 1517.60p. The Director now holds 949,935 shares. NOTE: Sold to meet tax...

Emma Walmsley, Chief Executive Officer, exercised 51,830 shares in the company on the 18th February 2019 at a price of 0.00p. The Director now holds 704,632 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, sold post-exercise 24,398 shares in the company on the 18th February 2019 at a price of 1575.60p. The Director now holds 680,234 shares. NOTE: Sold to meet...

Emma Walmsley, Chief Executive Officer, sold 66,159 shares in the company on the 15th February 2019 at a price of 1584.62p. The Director now holds 652,802 shares. NOTE: Sold to meet tax...

HSBC today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1860p (from 1820p). Story provided by StockMarketWire.com Broker Forecasts data...

Sir Philip Hampton, Chairman, bought 2,926 shares in the company on the 6th February 2019 at a price of 1495.00p. The Director now holds 51,451 shares representing 0.00% of the shares in issue....

Manvinder Banga, Non Executive Director, bought 481 shares in the company on the 6th February 2019 at a price of 1495.00p. The Director now holds 3,403 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 355 shares in the company on the 6th February 2019 at a price of 1495.00p. The Director now holds 3,632 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 355 shares in the company on the 6th February 2019 at a price of 1495.00p. The Director now holds 3,632 shares representing 0.00% of the shares in...

GlaxoSmithKline posted a 36% rise in pre-tax profit, underpinned higher sales of its shingles vaccine and respiratory disease treatments, but warned of lower earnings in 2019. Pre-tax profit for...

GlaxoSmithKline agreed to offer Merck up to €3.7bn (£3.2bn) to form a partnership to develop an immonutherapy for the treatment of cancer. The deal involved GSK making an upfront payment to Merck...

GlaxoSmithKline said it had completed the acquisition of oncology-focused Tesaro for around $5.1bn (£4.0bn). The transaction was first announced in December. At 2:28pm: (LON:GSK) GlaxoSmithKline...

There was little sign of progress on Brexit after Theresa May lost a key vote on her withdrawal bill last week. The FTSE 100 was broadly unmoved at 6,970 although this was better than a sea of red...

The FTSE 100 was up 0.15% to 6,978.52 by midday amid volatile trading in sterling as Theresa May prepares to go back to MPs with a plan B on Brexit. Other European markets were in the red after...

UK stocks started the week in positive territory Monday as continued Brexit uncertainty weighed on the pound, helping exporters, and investors held out hope that China and the US would strike a...

GlaxoSmithKline said chairman Philip Hampton would stand down following the pharmaceutical company's decision to separate out its consumer health business. A search for Hampton's successor was...

Emma Walmsley, Chief Executive Officer, has re-invested 1,536 shares in the company on the 11th January 2019 at a price of 1528.75p. The Director now holds 526,361 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,051 shares in the company on the 11th January 2019 at a price of 1528.75p. The Director now holds 694,100 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, has re-invested 1,588 shares in the company on the 11th January 2019 at a price of 1536.00p. The Director now holds 524,825 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,457 shares in the company on the 11th January 2019 at a price of 1536.00p. The Director now holds 691,055 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,994 shares in the company on the 11th January 2019 at a price of 1536.00p. The Director now holds 693,049 shares. Story provided by...

GlaxoSmithKline said it had extended its $5.1bn takeover bid for Tesaro until Thursday to accommodate related regulatory procedures in Europe. The bid was originally scheduled to expire late on...

Emma Walmsley, Chief Executive Officer, has re-invested 18 shares in the company on the 10th January 2019 at a price of 1524.40p. The Director now holds 523,229 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 24 shares in the company on the 10th January 2019 at a price of 1524.40p. The Director now holds 689,590 shares. Story provided by...

A bounce back in commodity prices lifted the mining sector, helping the FTSE 100 rise 0.9% to 6,765. Among the biggest risers were Evraz, Glencore and Rio Tinto with gains of at least 2.1% each....

The FTSE 100 was gathering strength by midday, up 0.9% to 6,762.04, investors hoping today's expected rate hike from the US Federal Reserve will be accompanied by guidance for a slower pace of...

UK stocks opened stronger on Wednesday after merger news boosted healthcare stocks and investors braced for a Fed rates decision due later in the day. At 0850, the benchmark FTSE 100 index was up...

GlaxoSmithKline reached agreement with Pfizer on Wednesday to combine their consumer health businesses into a new joint venture. Under the agreement, GSK would have a majority controlling equity...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1750p (from 1725p). Story provided by StockMarketWire.com Broker...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1520p (from 1525p). Story provided by StockMarketWire.com Broker Forecasts...

Barclays Capital today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to equal weight (from overweight). Story provided by StockMarketWire.com Broker Forecasts data provided by...

The FTSE 100 continued to enjoy gains following a temporary truce in the US-China trade war over the weekend, which could boost growth and support demand for resources. Saudi Arabia and Russia...

Pharmaceutical giant GlaxoSmithKline said it had agreed to acquire US oncology-focused company Tesaro for around $5.1bn (£4.0bn). GSK said the deal would significantly strengthen its...

HSBC today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 2000p (from 2030p). Story provided by StockMarketWire.com Broker Forecasts data...

UK stocks rose slightly on Monday led by heavyweight defensive sectors such as healthcare and tobacco along with a few banks. Just before midday, the benchmark FTSE 100 index was up 23 points or...

Sir Philip Hampton, Chairman, bought 2,867 shares in the company on the 31st October 2018 at a price of 1526.00p. The Director now holds 49,525 shares representing 0.00% of the shares in issue....

Manvinder Banga, Non Executive Director, bought 471 shares in the company on the 31st October 2018 at a price of 1526.00p. The Director now holds 2,922 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 348 shares in the company on the 31st October 2018 at a price of 1526.00p. The Director now holds 3,277 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 348 shares in the company on the 31st October 2018 at a price of 1526.00p. The Director now holds 3,277 shares representing 0.00% of the shares in...

GlaxoSmithKline and Pfizer's ViiV Healthcare released positive results of a study testing the effectiveness of fostemsavir in heavily treatment-experienced HIV patients. Fostemsavir, in...

GlaxoSmithKline slightly upgraded its annual guidance after bumper sales of its shingles vaccine Shingrix helped it boost third-quarter operating profit by 2%. Operating profit for the three...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer had reported positive results from a study of a long-acting and injectable two-drug regime for the treatment of HIV. The...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer had presented positive study results for an HIV treatment regime at a conference in Glasgow. ViiV presented three-year results...

Simon Dingemans, Financial Director, has re-invested 2,083 shares in the company on the 12th October 2018 at a price of 1451.60p. The Director now holds 689,550 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, bought 1,588 shares in the company on the 12th October 2018 at a price of 1458.79p. The Director now holds 521,536 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,086 shares in the company on the 11th October 2018 at a price of 1458.79p. The Director now holds 685,949 shares. Story provided by...

GlaxoSmithKline said European regulators had issued a positive opinion of a treatment for chronic obstructive pulmonary disease. The European Medicines Agency's Committee for Medicinal Products...

Glaxosmithkline said its ViiV Healthcare joint venture had submitted a marketing authorisation application to the European Medicines Agency for a single-tablet, two-drug regimen for the treatment...

UK stocks opened broadly flat on Monday as investors digested the rise of the far right in Swedish elections and US-China trade war fears continued to simmer. At 0850, the benchmark FTSE 100 index...

GlaxoSmithKline said Monday its severe asthma treatment did not pass regulatory hurdles in the US as the Food and Drug Administration requested more clinical data to support the approval. GSK...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1725p (from 1775p). Story provided by StockMarketWire.com Broker...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1525p. Story provided by StockMarketWire.com Broker Forecasts data provided...

GlaxoSmithKline said Thursday the European Commission had granted the company approval to market its severe asthma treatment for paediatric patients across 31 European countries. Following the...

Liberum Capital today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to hold (from buy) and raised its price target to 1700p (from 1630p). Story provided by...

There was a sea of red on the global markets as a toxic combo of a strong dollar, falling copper price and concern over Turkey's crisis and slower Chinese growth hit investor sentiment. Copper...

A slump in the mining sector on lower copper prices dragged the FTSE 100 down 0.8% to 7,548 around midday on a quiet day for corporate news. Copper cheapened 2.3% to $2.61 per pound and gold shed...

UK stocks had a directionless open on Wednesday as investors continued to fret about a potential global fallout from Turkey's currency crisis and lower metal prices hurt miners. At 0858, the...

GlaxoSmithKline said Wednesday its joint venture ViiV Healthcare revealed that its two-drug treatment for HIV from the Atlas study had met its primary goal after demonstrating a similar level of...

GlaxoSmithKline said Tuesday that Iain Mackay had been appointed Chief Financial Officer and was expected to join the company on 14 January 2019. Mackay joined GSK from the global bank HSBC, where...

Simon Dingemans, Financial Director, has re-invested 1,895 shares in the company on the 12th July 2018 at a price of 1576.60p. The Director now holds 684,814 shares. Story provided by...

UBS today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1700p (from 1600p). Story provided by StockMarketWire.com Broker Forecasts data...

GlaxoSmithKline said European regulators had issued a positive opinion of a new asthma treatment for children. The European Medicines Agency had recommending Nucala as an add-on treatment for...

Credit Suisse today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1600p (from 1450p). Story provided by StockMarketWire.com Broker...

Shore Capital today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to buy (from hold). Story provided by StockMarketWire.com Broker Forecasts data provided by...

Ongoing concerns about a US-driven trade war came back to haunt the markets again. Miners and industrial companies weighed on the FTSE 100, together with weakness among UK banks. The blue chip...

Sir Philip Hampton, Chairman, bought 2,810 shares in the company on the 25th July 2018 at a price of 1557.00p. The Director now holds 46,658 shares representing 0.00% of the shares in issue....

Manvinder Banga, Non Executive Director, bought 462 shares in the company on the 25th July 2018 at a price of 1557.00p. The Director now holds 2,451 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 341 shares in the company on the 25th July 2018 at a price of 1557.00p. The Director now holds 2,929 shares representing 0.00% of the shares in...

Urs Rohner, Non Executive Director, bought 462 shares in the company on the 25th July 2018 at a price of 1557.00p. The Director now holds 7,112 shares representing 0.00% of the shares in issue....

GlaxoSmithKline upgraded its annual earnings guidance after bumper sales of its shingles vaccine helped it boost second-quarter earnings. The pharmaceuticals giant also said it had made a $300m...

GlaxoSmithKline said Tuesday that its two-drug treatment for HIV, met its primary goal after demonstrating a similar level of efficiency to a three-drug regimen, with no emergence of resistance....

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1525p (from 1420p). Story provided by StockMarketWire.com Broker Forecasts...

Emma Walmsley, Chief Executive Officer, has re-invested 1,450 shares in the company on the 16th July 2018 at a price of 1570.91p. The Director now holds 518,394 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 992 shares in the company on the 16th July 2018 at a price of 1570.91p. The Director now holds 682,919 shares. Story provided by...

Citigroup today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1600p (from 1400p). Story provided by StockMarketWire.com Broker Forecasts...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1730p (from 1700p). Story provided by StockMarketWire.com Broker...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1525p (from 1420p). Story provided by StockMarketWire.com Broker Forecasts...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1700p (from 1500p). Story provided by StockMarketWire.com Broker...

The FTSE 100 remained in negative territory as weakness among mining stocks continued. Antofagasta (ANTO) fell 2.5% to £10.54 and Glencore (GLEN) lost 2.2% to 389.3p. BHP Billiton (BLT) and Rio...